雜志介紹

Cancer Letters雜志介紹

《Cancer Letters》是一本以English為主的未開(kāi)放獲取國(guó)際優(yōu)秀期刊，中文名稱(chēng)癌癥快報(bào)，本刊主要出版、報(bào)道醫(yī)學(xué)-ONCOLOGY領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果，介紹該領(lǐng)域有關(guān)本專(zhuān)業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用，也得到了本專(zhuān)業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為9.1，最新CiteScore 指數(shù)為17.7。

本刊近期中國(guó)學(xué)者發(fā)表的論文主要有：

• Patient-derived organoids in translational oncology and drug screening

  Author: Yang, Ruixin; Yu, Yingyan

• PIWI-interacting RNAs: Critical roles and therapeutic targets in cancer

  Author: Zhou, Jialin; Xie, Han; Liu, Jun; Huang, Ruixiang; Xiang, Yufei; Tian, Dasheng; Bian, Erbao

• Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions

  Author: Zhang, Chenyue; Zhang, Chenxing; Wang, Haiyong

• Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers

  Author: Shi, Fukang; Huang, Xing; Hong, Zhengtao; Lu, Na; Huang, Xin; Liu, Lingyue; Liang, Tingbo; Bai, Xueli

英文介紹

Cancer Letters雜志英文介紹

CANCER LETTERS is a journal providing rapid publication of full-length articles in the broad area of cancer research. The journal places emphasis on the molecular and cell biology of cancer, oncogenes, carcinogenesis, radiation biology, molecular pathology, hormones and cancer, viral oncology, biology of cancer and metastasis, molecular cytogenetics, epidemiology; and experimental therapeutics. The primary criterion for publication is interest to a multidisciplinary audience. Papers should be technically sound and substantiated by sufficient experimental detail. Clinical papers will be accepted if they contribute to the understanding of the basic mechanisms underlying disease.